IDH1 and central nervous system cancer: It has been shown that treatment with CB839 radiosensitised IDH1 mutant cells in an in vivo model, resulting in tumour growth inhibition of IDH1 mutant gliomas but not of wild-type tumours (McBrayer et al., 2018).